International Concerted Action to Allocate Children, Adolescents and Young Adults With Relapsed and Refractory Leukemia/Lymphoma to the Right Therapy

What this Trial Is About

Researchers are evaluating a new approach called the international Leukemia Target Board (iLTB) for children, adolescents, and young adults with relapsed or refractory blood cancers. The iLTB aims to bring together experts across Europe to review molecular, immunophenotypic, and drug response data from each patient to prioritize potential treatment options. This non-interventional study seeks to provide uniform advice to treating physicians and facilitate access to early phase clinical trials or alternative treatments when standard options are limited. The iLTB does not provide treatments directly but serves as a platform where experts discuss patients' genetic lesions, surface antigen markers, and drug response profiles. Patients eligible for discussion have relapsed or refractory hematological malignancies and have undergone molecular profiling and flow cytometry. The expert panel uses a prioritization algorithm to recommend potential therapies or trial options, considering each patient's treatment history and goals. Patient data is shared following informed consent and feedback is given to the treating physician. Participants are involved through data sharing and expert review of their tumor profiles, but no treatment is administered by the study itself. The study tracks how often physicians follow the iLTB advice, what therapies are chosen, and patient outcomes over time. The main measure is the proportion of patients receiving therapy aligned with iLTB recommendations, monitored over about 8 years. This long-term registry helps assess the impact of expert advice on treatment decisions and outcomes for this challenging patient group.

International Leukemia Target Board